21
Thomas Julius Borody, Walter George Shortis, Nicolas Peter Shortis: Picosulfate-containing preparation for colonic evacuation. January 12, 1999: US05858403 (42 worldwide citation)

An osmotic colonic evacuant in solid dosage form, which comprises a phosphate based laxative or a sulfate based laxative and preferably comprises sodium picosulfate and an antacid, is used preferably in conjunction with 250 ml to 1,500 ml diluent, alone or as part of a sequential pack, to evacuate t ...


22
Wallace John L, Cirino Giuseppe, Caliendo Giuseppe, Sparatore Anna, Santagada Vincenzo, Fiorucci Stefano: Derivatives of 4- or 5-aminosalicylic acid. Antibe Therapeutics, Wallace John L, Cirino Giuseppe, Caliendo Giuseppe, Sparatore Anna, Santagada Vincenzo, Fiorucci Stefano, BENNETT JONES, November 30, 2006: WO/2006/125293 (42 worldwide citation)

The present invention provides new derivatives of 4- or 5-aminosalicylic acid, and a pharmaceutical composition containing these derivatives of 4- or 5-aminosalicylic acid as active ingredients, useful for the treatment of intestinal diseases such as inflammatory bowel disease (IBD) and irritable bo ...


23
Hulin Bernard: Dipeptidyl peptidase iv inhibiting fluorinated cyclic amides. Pfizer Products, Hulin Bernard, LUMB J Trevor, June 3, 2004: WO/2004/046106 (41 worldwide citation)

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, suc ...


24
Jean Michel Vernier, Nicholas D P Cosford, Ian A McDonald: Substituted pyridine compounds useful as modulators of acetylcholine receptors. Merck & Co, David Rubin, David L Rose, October 14, 2003: US06632823 (40 worldwide citation)

In accordance with the present invention, a novel class of substituted pyridine compounds (optionally containing ether, ester, amide, ketone or thioether substitutions) that promote the release of ligands involved in neurotransmission have been discovered. In a particular aspect compounds of the pre ...


25
William Dennis Allen, Margaret Anneli Linggood, Philip Porter: Priobiotic containing enterococcus faecium strain NCIMB 40371. Unilever Patent Holdings, Cushman Darby & Cushman IP Group Pillsbury Madison & Sutro, March 17, 1998: US05728380 (40 worldwide citation)

A strain of Enterococcus faecium, deposited as NCIMB 40371, has valuable probiotic properties and is particularly effective in alleviating symptoms of irritable bowel syndrome (IBS) in human patients. The strain can be used in the manufacture of human foodstuffs.


26
Hulin Bernard, Parker Janice C: Fluorinated lysine derivatives as dipeptidyl peptidase iv inhibitors. Pfizer Products, Hulin Bernard, Parker Janice C, FULLER Grover F Jr, March 3, 2005: WO/2005/019168 (40 worldwide citation)

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV ('DPP-IV')of formula (Ia) and (Ib), pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are s ...


27
Ernst Glen, Phillips Eifion, Schmiesing Richard: Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists. Astrazeneca, Ernst Glen, Phillips Eifion, Schmiesing Richard, ASTRAZENECA, February 26, 2004: WO/2004/016617 (40 worldwide citation)

Nicotinic acetylcholine receptor of formula (I) wherein D, Ar1, E and Ar2 are as defined in the specification, enantiomers, pharmaceutically acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same in the treatment or prophylaxis of psychotic disorde ...


28
John L Wallace, Giuseppe Cirino, Giuseppe Caliendo, Anna Sparatore, Vincenzo Santagada, Stefano Fiorucci: Derivatives of 4- or 5-aminosalicylic acid. Antibe Therapeutics, Bennett Jones, March 22, 2011: US07910568 (39 worldwide citation)

The present invention provides new derivatives of 4- or 5-aminosalicylic acid, and a pharmaceutical composition containing these derivatives of 4- or 5-aminosalicylic acid as active ingredients, useful for the treatment of intestinal diseases such as inflammatory bowel disease (IBD) and irritable bo ...


29
Burkhard Goeke, Joerg Schirra: Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility. Amylin Pharmaceuticals, McKee Voorhees & Sease, June 17, 2003: US06579851 (39 worldwide citation)

The present invention provides an effective method for inhibiting antro-duodenal motility in healthy subjects and patients suffering from various disorders, without the side effects associated with other pharmaceutical compositions. GLP1(7-36)amide slows antro-duodenal motility and may be used for t ...


30
Henry C Lin, Mark Pimentel: Methods of diagnosing small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions. Cedars Sinai Medical Center, Seth D Levy, Davis Wright Tremaine, June 15, 2010: US07736622 (38 worldwide citation)

Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory ...